Medindia

X

Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference

Monday, December 7, 2009 General News J E 4
Advertisement


CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the Deutsche Bank 2009 MedTools Investor Conference to be held at the Intercontinental Hotel in Boston, Mass. on December 9-10, 2009.

Genoptix's EVP and COO, Sam Riccitelli, will be in attendance to represent the Company on Wednesday, December 9, 2009. He will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Studies Support Use of Intravenous Vimpat(R) (...
S
Concord Coalition Report Shows Eagerness for Refor...